Business Description
CEL-SCI Corp
NAICS : 541713
SIC : 2836
ISIN : US1508376076
Total Employee Number:
44Description
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 1.24 | |||||
Debt-to-EBITDA | -0.46 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.5 | |||||
3-Year EPS without NRI Growth Rate | 38 | |||||
3-Year FCF Growth Rate | 31.5 | |||||
3-Year Book Growth Rate | -55.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.07 | |||||
9-Day RSI | 37.81 | |||||
14-Day RSI | 39.02 | |||||
3-1 Month Momentum % | -60.14 | |||||
6-1 Month Momentum % | -69.27 | |||||
12-1 Month Momentum % | -81.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.6 | |||||
Quick Ratio | 0.54 | |||||
Cash Ratio | 0.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -76.9 | |||||
Shareholder Yield % | -112.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -231.67 | |||||
ROA % | -102.35 | |||||
ROIC % | -115.66 | |||||
3-Year ROIIC % | -143.92 | |||||
ROC (Joel Greenblatt) % | -170.35 | |||||
ROCE % | -130.86 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.2 | |||||
Price-to-Tangible-Book | 1.22 | |||||
EV-to-EBIT | -1.07 | |||||
EV-to-EBITDA | -1.29 | |||||
EV-to-Forward-Revenue | 2.79 | |||||
EV-to-FCF | -1.42 | |||||
Earnings Yield (Greenblatt) % | -93.46 | |||||
FCF Yield % | -97.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CEL-SCI Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.988 | ||
| Beta | 1.8702 | ||
| 3-Year Sharpe Ratio | -1.43 | ||
| 3-Year Sortino Ratio | -1.69 | ||
| Volatility % | 52.63 | ||
| 14-Day RSI | 39.02 | ||
| 14-Day ATR (€) | 0.160692 | ||
| 20-Day SMA (€) | 1.1025 | ||
| 12-1 Month Momentum % | -81.26 | ||
| 52-Week Range (€) | 0.765 - 9.7 | ||
| Shares Outstanding (Mil) | 17.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CEL-SCI Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CEL-SCI Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-08-14 | In 48 days | ||
| General meeting for 2026 | 2026-06-30 | In 3 days | ||
| Second quarter earnings results for 2026 | 2026-05-15 | 1.10 (+0.92%) | ||
| First quarter earnings results for 2026 | 2026-02-17 | 3.72 (+0.00%) | ||
| Annual report for 2025 | 2025-12-29 | 3.58 (+0.00%) | ||
| LD Micro Main Event | 2025-10-21 09:30 | 7.50 (+1.35%) | ||
| Third quarter earnings results for 2025 | 2025-08-14 | 5.87 (+0.00%) | ||
| 0.0333333:1 Stock Split | 2025-05-20 | 5.87 (+0.00%) | ||
| General meeting for 2025 | 2025-05-19 11:00 | 5.95 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-05-14 | 6.68 (+0.63%) |
Show
Entries
CEL-SCI Corp Frequently Asked Questions
What is CEL-SCI Corp(FRA:LSR)'s stock price today?
The current price of FRA:LSR is €0.76. The 52 week high of FRA:LSR is €9.70 and 52 week low is €0.77.
When is next earnings date of CEL-SCI Corp(FRA:LSR)?
The next earnings date of CEL-SCI Corp(FRA:LSR) is 2026-08-14 Est..
Does CEL-SCI Corp(FRA:LSR) pay dividends? If so, how much?
CEL-SCI Corp(FRA:LSR) does not pay dividend.
Press Release
Articles on CEL-SCI Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers